For the year ending 2025-12-31, JAGX had -$170K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net comprehensive loss | -54,408 |
| Changes in fair value of freestanding and hybrid financial instruments designated at fair value option | -6,266 |
| Provision for inventory obsolescence | 2,000 |
| Depreciation and amortization expenses | 1,913 |
| Loss (gain) on extinguishment of debt | -1,799 |
| Stock-based compensation, vested and released restricted stock units, and exercised stock options | 831 |
| Impairment loss on indefinite-lived intangible assets | 800 |
| Amortization of operating lease - right-of-use asset | 289 |
| Share in joint venture's loss | -162 |
| Amortization of debt issuance costs, debt discount, and non-cash interest expense | 153 |
| Accounts receivable | -6 |
| Other receivable | 45 |
| Inventory | 254 |
| Prepaid expenses and other current assets | -10,670 |
| Other assets | -1,173 |
| Accounts payable | 3,346 |
| Accrued liabilities | 2,056 |
| Deferred revenue | -171 |
| Operating lease liability | -272 |
| Total cash used in operating activities | -23,686 |
| Purchase of furniture and fixtures | 41 |
| Total cash used in investing activities | -41 |
| Proceeds from new note-Streeterville Capital Llc | 10,000 |
| Proceeds from issuance of shares in at the market offering, net of issuance and offering costs of 145 and 157 in 2025 and 2024, respectively | 6,291 |
| Proceeds from convertible notes | 3,445 |
| Proceeds from issuance of preferred shares in pipe financing, net of issuance cost | 2,377 |
| Net proceeds-Placement Agent | 1,309 |
| Net proceeds-Brown Stone Capital Limited | 1,000 |
| Repayment of insurance financing | 652 |
| Payment of tempesta note | 50 |
| Payment of convertible notes | 50 |
| Total cash provided by financing activities | 23,670 |
| Effects of foreign exchange rate changes on assets and liabilities | -113 |
| Net increase (decrease) in cash and restricted cash | -170 |
| Cash and restricted cash at beginning of the period | 8,002 |
| Cash and restricted cash at end of the period | 7,832 |
Jaguar Health, Inc. (JAGX)
Jaguar Health, Inc. (JAGX)